Search The Medical Knowledge Base

Drug Details

Acea 0.75% w/w Gel

• Generic Name
  Metronidazole 0.75% w/w
• Presentation
  Gel. Clear very pale yellow gel.
• Description
  Acea 0.75% w/w Gel Metronidazole 0.75% w/w Gel
• Indications
  

  The treatment of acute inflammatory exacerbations of rosacea.

• Adult Dosage
  

   

  For cutaneous use only. (i) For adults and the elderly. Apply the gel to the affected area of the skin in a thin film twice daily for 8 weeks. Thereafter further applications may be necessary depending on the severity of the condition. (ii) For Children. Not recommended.

• Child Dosage
  

   

  For cutaneous use only. (i) For adults and the elderly. Apply the gel to the affected area of the skin in a thin film twice daily for 8 weeks. Thereafter further applications may be necessary depending on the severity of the condition. (ii) For Children. Not recommended.

• Elderly Dosage
  

   

  For cutaneous use only. (i) For adults and the elderly. Apply the gel to the affected area of the skin in a thin film twice daily for 8 weeks. Thereafter further applications may be necessary depending on the severity of the condition. (ii) For Children. Not recommended.

• Contra Indications
  

  Known hypersensitivity to metronidazole, parabens or any of the constituents.

  
  

• Special Precautions
  

  Warnings: Avoid contact with the eyes. If contact with the eyes occurs the gel should be washed out carefully with water.

  Precautions: The following statements take into account the possibility that metronidazole may be absorbed after topical application. However there is no evidence of any significant systemic concentrations of metronidazole following topical applications. Peripheral neuropathy has been reported in association with prolonged use of oral metronidazole. The elimination half-life of metronidazole remains unchanged in the presence of renal failure. Such patients, however, retain the metabolite of metronidazole. The clinical significance of this is not known at present. However in patients undergoing haemodialysis, metronidazole and its metabolites are efficiently removed.

  Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) and ethyl parahydroxybenzoate (E214), may cause allergic reactions (possibly delayed).

• Interactions
  

  Patients are advised not to take alcohol during systemic metronidazole therapy because of the possibility of a disulfiram-like reaction.

  Some potentiation of anti-coagulant therapy has been reported when metronidazole has been used with the warfarin type oral anticoagulants.

  Patients receiving phenobarbitone metabolise metronidazole at a much faster rate than normal, reducing the half-life to 3 hours.

• Adverse Drug Reactions
  

  Dryness or irritation of the skin may be experienced after application to unbroken skin. Systemic metronidazole therapy may occasionally cause an unpleasant taste in the mouth, furred tongue, nausea, vomiting, gastro-intestinal disturbance, urticaria, angioedema and anyphylaxis. Drowsiness, dizziness, headache, ataxia, skin rash, pruritis and darkening of urine has been reported, but rarely.